[Asia Economy Reporter Jang Hyowon] The U.S. Food and Drug Administration (FDA) has released an analysis stating that the benefits of Pfizer's COVID-19 vaccine for children outweigh the risks.
According to foreign media on the 22nd (local time), the FDA stated in a report that administering Pfizer's vaccine to children aged 5 to 11 at one-third (10㎍) of the adult dose carries such benefits.
The FDA analyzed that in most scenarios under these conditions, the benefits of preventing death or hospitalization due to COVID-19 outweigh the risks of side effects such as myocarditis.
The decision on the emergency use authorization of Pfizer's vaccine for children aged 5 to 11 is expected to be finalized following the judgment of the FDA's external advisory committee on the 26th. In this report, the FDA did not explicitly state a position on whether to allow emergency authorization for this age group.
Meanwhile, Pfizer explained in the data that in a clinical trial involving 2,268 children aged 5 to 11, administering one-third of the adult dose resulted in an estimated COVID-19 prevention efficacy of 90.7%.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
